Every material Form 8-K Xenon Pharmaceuticals Inc. has filed with the SEC since May 07, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xenon reported third-quarter 2026 results with no revenue in either period, a net loss of $110.4 million versus $90.9 million a year earlier, and higher research and development and general and administrative spending. Loss per share narrowed to $1.11 from $1.15, and the company said its cash funds operations into 2029. Shareholders should note that the X-NOVA2 depression study readout is now expected in December 2026 and that enrollment of new patients in the depression and bipolar Phase 3 studies was paused in September.
Net loss was $110.4 million for Q3 2026 versus $90.9 million for Q3 2025; loss per share was $1.11 versus $1.15.
No revenue was recorded in Q3 2026 or Q3 2025. Research and development expenses rose to $95.6 million from $77.1 million.
Cash, cash equivalents and marketable securities were $1,153.5 million at September 30, 2026, compared with $586.0 million at December 31, 2025.
The azetukalner New Drug Application for focal seizures was submitted to the FDA in September 2026; X-NOVA2 topline data are now expected in December 2026.
Xenon Pharmaceuticals reported a second-quarter 2026 net loss of $110.7 million, or $1.11 per share, up from $84.7 million, or $1.07 per share, a year earlier, as research and development spending rose to $99.2 million. The company had no revenue in the quarter, and it said it remains on track to submit an NDA for azetukalner in the third quarter of 2026, with cash of $1.2 billion and runway into 2029.
Q2 2026 net loss was $110.7 million ($1.11 per share), compared with $84.7 million ($1.07 per share) in Q2 2025.
Research and development expenses were $99.2 million, up from $75.0 million, driven by azetukalner Phase 3 studies and NDA manufacturing activities.
Cash, cash equivalents and marketable securities were $1,245.1 million as of June 30, 2026, versus $586.0 million at December 31, 2025, with runway into 2029.
The company said lower revenue from its Neurocrine Biosciences collaboration contributed to the larger loss.
At its annual meeting on June 2, 2026, Xenon Pharmaceuticals shareholders approved a new 2026 Equity Incentive Plan to replace the 2014 plan, and elected all eight director nominees. Shareholders also approved the auditor appointment and backed an annual frequency for future say-on-pay votes on executive pay.
Shareholders holding about 93.54% of the company's total voting common shares were present or represented at the meeting.
The 2026 Equity Incentive Plan received 58,579,810 votes for and 27,570,443.18 votes against, with 842,250 abstentions.
Eight directors, including Dawn Svoronos and Patrick Machado, were elected to serve until the 2027 annual meeting.
Shareholders voted for a one-year frequency for say-on-pay votes, with 86,918,084.18 votes, and PricewaterhouseCoopers LLP was approved as auditor.
Xenon Pharmaceuticals reported a first-quarter 2026 net loss of $102.3 million, up from $65.0 million a year earlier, and no revenue compared with $7.5 million in the prior-year quarter. The company attributed the larger loss mainly to higher research and development spending on its Phase 3 azetukalner studies, higher personnel costs, and lower collaboration revenue from Neurocrine Biosciences. Cash, cash equivalents and marketable securities of $1.3 billion are expected to fund operations into 2029, and the company plans to submit a New Drug Application for azetukalner in focal onset seizures in the third quarter of 2026.
Net loss was $102.3 million, or $1.17 per share, for the three months ended March 31, 2026, versus $65.0 million, or $0.83 per share, a year earlier.
Revenue was $0 in the quarter, compared with $7.5 million in the first quarter of 2025.
Research and development expenses rose to $88.5 million from $61.2 million, and general and administrative expenses rose to $23.8 million from $19.0 million.
Cash and marketable securities were $1,339.6 million at March 31, 2026, including $707.6 million from a public offering and $130.0 million from the ATM program during the quarter.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xenon Pharmaceuticals Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →